Login
Zimmer Biomet NYSE: ZBH
Zimmer Biomet designs, manufactures and markets effective, innovative solutions that support orthopaedic surgeons and clinicians in alleviating pain and improving the quality of life for people around the world. Our musculoskeletal technologies make us partners to healthcare providers in more than 100 countries
| Name | Zimmer Biomet |
| Ticker | ZBH |
| Exchange | NYSE |
| Sector | Health Care |
| Industry | Medical Devices |
|
Price
52W Low/High |
171.76
109.26 / 171.76 |
| Momentum | Neutral |
| Market cap | 36 B |
| 1Y Total Return |
57.99%
Average |
| 1Y Volatility |
34.86%
Less Risk |
Zimmer Biomet designs, manufactures and markets effective, innovative solutions that support orthopaedic surgeons and clinicians in alleviating pain and improving the quality of life for people around the world. Our musculoskeletal technologies make us partners to healthcare providers in more than 100 countries
Details
| Ticker | ZBH |
| Name | Zimmer Biomet |
| ISIN | US98956P1021 |
| CUSIP | 98956P102 |
| Exchange | NYSE |
| Sector | Health Care |
| Industry | Medical Devices |
| Country | USA |
| Currency | U.S. Dollar |
Share as of 4/15/21
| Close Price | 171.76 |
| 52W Low/High | 109.26 / 171.76 |
| Market cap | 36 B |
| 1Y Total Return |
57.99%
Average |
| 1Y Volatility |
34.86%
Less Risk |
| Beta | 1.14 |
| PE (trailing) | - |
| 12M Dividends | 0.96 |
| Last Dividend Date | 3/26/21 |
| Dividend Yield | 0.56% |
Fin. Strength
| Net Profit Margin | -2.2% |
| Cash from Op. / Cur. Liabilities | 0.53 |
| Diluted Earnings / Share | -0.76 |
| ROE | - |
| ROIC | 0.1% |
| Price / Revenue | 5.1 |
| Price / Book | 3.0 |
| Price / CF | 29.8 |
| Current Ratio | 2.3 |
| Cur.Liabilities / Tot.Liabilities | 0.2 |
| Financial Leverage | 0.70 |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
7,065
|
7,928
|
7,930
|
7,733
|
7,604
|
5,287
|
|
| Gross Profit |
5,002
|
5,674
|
5,650
|
5,569
|
5,175
|
3,842
|
|
| R&D |
393
|
429
|
386
|
371
|
356
|
229
|
|
| EBITDA |
1,050
|
1,003
|
1,818
|
2,005
|
1,933
|
946
|
|
| Operating Income |
8
|
10
|
784
|
1,018
|
856
|
480
|
|
| Net Income exc. Extra |
-
|
-
|
1,753
|
652
|
363
|
174
|
|
| per Share | |||||||
| Diluted avg Shares |
209
|
207
|
205
|
204
|
203
|
206
|
|
| EPS exc. Extra |
-0.76
|
-0.48
|
8.58
|
3.19
|
1.82
|
1.00
|
|
| Dividend |
0.96
|
0.96
|
0.96
|
0.96
|
0.94
|
0.88
|
|
| Div. Yield (an.) |
0.71%
|
0.70%
|
0.73%
|
0.82%
|
0.72%
|
0.94%
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
24,026
|
24,315
|
25,382
|
26,418
|
27,037
|
26,689
|
|
| Cash, Eq & Invt ShortTerm |
967
|
513
|
525
|
481
|
489
|
1,810
|
|
| Total Current Assets |
5,153
|
4,402
|
4,513
|
4,433
|
4,698
|
6,395
|
|
| Total Non-Current Assets |
18,873
|
19,914
|
20,869
|
21,984
|
22,338
|
20,294
|
|
| Intangibles |
15,889
|
16,885
|
18,421
|
19,370
|
19,771
|
17,503
|
|
| Total Liabilities |
12,147
|
12,230
|
13,159
|
15,967
|
17,290
|
16,696
|
|
| Total Current Liabilities |
2,266
|
3,774
|
2,391
|
3,010
|
2,312
|
1,787
|
|
| Long Term Debt |
9,881
|
8,456
|
10,768
|
12,957
|
14,978
|
14,909
|
|
| Shareholder equity |
11,872
|
12,082
|
12,217
|
10,450
|
9,746
|
9,992
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
1,203
|
1,542
|
1,771
|
1,807
|
1,468
|
749
|
|
| Depreciation |
1,021
|
1,007
|
1,050
|
1,050
|
1,072
|
521
|
|
| Cash from Investing |
-436
|
-674
|
-462
|
-529
|
-1,476
|
-7,598
|
|
| Capex |
441
|
713
|
446
|
514
|
499
|
330
|
|
| Cash from Financing |
-318
|
-873
|
-1,260
|
-1,287
|
-973
|
7,382
|
|
| Stock Issued |
130
|
130
|
116
|
156
|
-424
|
107
|
|
| Debt (LT) Issued |
-223
|
-803
|
-1,155
|
-1,222
|
-359
|
7,432
|
|
| Free Cash Flow |
-1,677
|
1,653
|
2,221
|
2,528
|
2,030
|
-443
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
22.1%
|
8.4%
|
4.8%
|
3.3%
|
|
| NCFO / Op.Income |
14,490.4%
|
15,117.6%
|
225.8%
|
177.5%
|
171.4%
|
156.1%
|
|
| Current Ratio |
2.3
|
1.2
|
1.9
|
1.5
|
2.0
|
3.6
|
|
| Financial Leverage D/E |
0.70
|
0.69
|
0.75
|
1.00
|
1.19
|
1.19
|
|
| Return on Capital Avg |
0.1%
|
0.0%
|
10.4%
|
4.3%
|
1.2%
|
2.6%
|
|
| Return on Shareholder Equity |
-
|
-
|
15.5%
|
6.5%
|
3.7%
|
2.1%
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available